Author

Yanyan Lou

Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic Jacksonville, FL, USA;

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Alfredo Quinones-Hinojosa· 1 shared Binyan Zhao· 1 shared Hong Qin· 1 shared James W Jakub· 1 shared Julio C Chavez· 1 shared Loic Pierre DeleyrolleiD· 1 shared Maria Jose Ulloa-Navas· 1 shared Mieu BrooksiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Alfredo Quinones-Hinojosa

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A Standalone PD-1 Chimeric Switch Receptor T-Cell Platform Expands the Therapeutic Window of PD-L1 Targeting in Solid Tumors

Yan Luo, Shaohua Guo, Yaqing Qie, Binyan Zhao, Maria Jose Ulloa-Navas, Mieu Brooks, Vanessa Jones, Tanya Hundal, Julio C Chavez, Yanyan Lou, Loic Pierre Deleyrolle, Vamsidhar Velcheti, James W Jakub, Roxana Dronca, Mohamed A Kharfan-Dabaja, , Hong Qin

This paper develops a PD-1 chimeric switch receptor T-cell platform that improves tumor targeting while reducing toxicity to normal cells in PD-L1-targeted therapies.

bioRxiv · Nov 9, 2026 · PreprintMolecular Biology